Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 11/2015

01-11-2015 | Heart Failure (MR Mehra and E Joyce, Section Editors)

Emerging Advances in the Management of Cardiac Amyloidosis

Authors: Michael N. Vranian, Brett W. Sperry, Jason Valent, Mazen Hanna

Published in: Current Cardiology Reports | Issue 11/2015

Login to get access

Abstract

Amyloidosis is a disease in which proteins misfold, aggregate into fibrils, and deposit extracellularly disrupting organ architecture and function. There are two main types which affect the heart: light chain (AL) amyloidosis and transthyretin cardiac amyloidosis (ATTR). There is a misconception that cardiac amyloidosis has no effective treatment options. However, over the past decade, there has been extensive research and drug development. Outcomes are improving in AL amyloidosis with evolving chemotherapeutic regimens and novel monoclonal antibodies. In ATTR, therapies that decrease protein production, prevent dissociation, and promote clearance have the potential to slow or even halt a disease which is uniformly fatal. Selected patients may be candidates for heart and/or stem cell transplant and should be promptly referred to an experienced amyloid program. Herein, we discuss the emerging advances for the treatment of cardiac amyloidosis.
Literature
1.
2.
Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398–408.CrossRefPubMed
3.
4.
Molina OG, Judge D, Campbell W, Cahal H, Mugmon M. Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure. J Community Hosp Intern Med Perspect. 2014;4(5):25500.
5.
Poshusta TL, Sikkink LA, Leung N, et al. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS ONE. 2009;4(4), e5169.PubMedCentralCrossRefPubMed
6.
Leinonen H, Pohjola-Sintonen S. Cardiac amyloidosis. Therapeutic and diagnostic difficulties with reference to two different forms of the disease. Acta Med Scand. 1986;219(1):125–8.CrossRefPubMed
7.•
Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9. Important trial updating the Mayo prognostic criteria for amyloidosis with serum free light chain assessment.CrossRefPubMed
8.
Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426–30.CrossRefPubMed
9.•
Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–28. Most recent consensus document on defining organ involvement in amyloidosis.CrossRefPubMed
10.
Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202–7.CrossRefPubMed
11.
Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99(4):743–50.PubMedCentralCrossRefPubMed
12.
Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557–61.CrossRefPubMed
13.
Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case–control study. Blood. 2004;103(10):3960–3.CrossRefPubMed
14.
Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110(10):3561–3.PubMedCentralCrossRefPubMed
15.
Kastritis E, Roussou M, Gavriatopoulou M, et al. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015;90(4):E60–5.CrossRefPubMed
16.
Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387–90.CrossRefPubMed
17.
Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4.PubMedCentralCrossRefPubMed
18.
Zonder JA, Sanchorawala V, Snyder RM, et al (2009) Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in al-amyloidosis with tolerable neurotoxicity. Blood (ASH Annual Meeting Abstracts) 114: Abstract 746
19.
20.
Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121:5124–30.CrossRefPubMed
21.
Conner R, Hosenpud JD, Norman DJ, et al. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant. 1988;7(2):165–7.PubMed
22.
Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation. 1991;84(5S):III338–43.PubMed
23.
Dubrey SW, Burke MM, Hawkins PN, et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23(10):1142–53.CrossRefPubMed
24.
Kpodonu J, Massad MG, Caines A, et al. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2005;24(11):1763–5.CrossRefPubMed
25.
Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant. 2008;27(8):823–9.CrossRefPubMed
26.
Dey BR, Chung SS, Spitzer TR, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010;90:905–11.PubMedCentralCrossRefPubMed
27.
Gilstrap LG, Niehaus E, Malhotra R, et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant. 2014;33(2):149–56.PubMedCentralCrossRef
28.
Wall JS, Kennel SJ, Williams A, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS ONE. 2012;7(12), e52686.PubMedCentralCrossRefPubMed
29.
Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119(23):5397–404.PubMedCentralCrossRefPubMed
30.
Zonder J, Houde C, Tuchman S, et al. A phase I trial of pomalidomide, bortezomib (Velcade), and dexamethasone (PVD) as initial treatment of AL amyloidosis and light chain deposition disease. Blood (ASH Annu Meet Abstr). 2014;124:4767.
31.
Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466–73.CrossRefPubMed
32.
Yamashita T, Hamidi AK, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid. 2005;12(2):127–30.CrossRefPubMed
33.
Buxbaum J et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol. 2006;47(8):1724–5.CrossRefPubMed
34.
Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40:242–6.CrossRefPubMed
35.
Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21:282–92.CrossRefPubMed
36.
Hamour IM, Lachmann HJ, Goodman HJB, et al. Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant. 2008;8(5):1056–9.CrossRefPubMed
37.
Roig E, Almenar L, Gonzalez-Vilchez F, et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant. 2009;9(6):1414–9.CrossRefPubMed
38.
Ammirati E, Marziliano N, Vittori C, et al. The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation. Amyloid. 2012;19(2):113–7.CrossRefPubMed
39.
Thenappan T, Fedson S, Rich J, et al. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis. Amyloid. 2014;21(2):120–3.CrossRefPubMed
40.•
Baures PW, Peterson SA, Kelly JW. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem. 1998;6:1389. This article and the next two from the lab of Dr. Kelly are excellent examples of years of basic science research translating into breakthrough therapy.CrossRefPubMed
41.
Munro SL, Lim CF, Hall JG, et al. Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine binding globulin. J Clin Endocrinol Metab. 1989;68:1141–7.CrossRefPubMed
42.
Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol. 2000;7:312–21.CrossRefPubMed
43.
Stone CA, Van Arman CG, Lotti VJ, et al. Pharmacology and toxicology of diflunisal. Br J Clin Pharmacol. 1977;4(Suppl1):19S–29.
44.••
Berk JL, Suhr OB, Obici L, et al. Diflunisal trial C. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–67. This is the only randomized placebo-controlled trial in transthyretin amyloidosis that has met its primary endpoint. This landmark clinical trial will likely lead to the approval of diflunisal for the indication of FAP.PubMedCentralCrossRefPubMed
45.
Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109:9629–34.PubMedCentralCrossRefPubMed
46.
Giampaolo M, Plante-Bordeneuve P, Judge DJ, et al. Effect of tafamidids on transthyretin stabilization and clinical outcomes in patients with Non-Val30MET transthyretin amyloidosis. J Cardiovasc Trans Res. 2013;6:1011–20.CrossRef
47.••
Coelho T, Maia LF, da Silva AM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology. 2012;79(8):785–92. This was the first randomized placebo-controlled trial in transthyretin amyloidosis. Although the primary endpoint was not met, the results led to the approval of tafamidis in Europe.PubMedCentralCrossRefPubMed
48.
Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Trans Res. 2015;88:117–27.CrossRef
49.
Maurer M, Grogan D, Judge D, et al. Tafamidis in transthyretin amyloid cardiomyopathy effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519–26.CrossRefPubMed
50.
Ferreira N, Cardoso I, Domingues MR, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 2009;583:3569–76.
51.
Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012;101:805–13.PubMedCentralCrossRefPubMed
52.
Siepen FA, Buss SJ, Andre F, et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of t1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol. 2015;104(8):640–7.CrossRef
53.
Mereles D, Buss SJ, Hardt SE, et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with al amyloidosis. Clin Res Cardiol. 2010;99:483–90.CrossRefPubMed
54.
Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329–40.CrossRefPubMed
55.
Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259–93.CrossRefPubMed
56.••
Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–29. This is a major breakthrough and publication in the field. A New England Journal of Medicine publication has brought transthyretin amyloidosis into greater awareness amongst physicians.CrossRefPubMed
57.
Coelho T, Suhr O, Coneicau I, et al. Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic for the treatment of familial amyloid polyneuropathy. Neurology. 2015;84(14):S9.003.
58.
Gagnon KT, Watts JK, On behalf of the Board of the Oligonucleotide Therapeutics Society. 10th Annual Meeting of the Oligonucleotide Therapeutics Society: session summary. Nucleic Acid Ther. 2014;24(6):428–34.CrossRef
59.
Ackerman EJ, Guo S, Booten S, et al. Clinical development of antisense therapy for the treatment of transthryetin-associated polyneuropathy. Amyloid. 2012;19(S1):43–4.CrossRef
60.
Tagliavini F, Forloni G, Colombo L, Salmona M, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol. 2000;300:1309–22.CrossRefPubMed
61.
Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006;20:234–9.CrossRefPubMed
62.
63.
Rodrigues CM, Sola S, Brito MA, et al. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun. 2001;281:468–74.CrossRefPubMed
64.
Sola S, Castro RE, Laires PA, et al. Tauroursodeoxycholic acid prevents amyloid beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003;9:226–34.PubMedCentralCrossRefPubMed
65.
Macedo B, Batista AR, Ferreira N, et al. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta. 1782;2008:517–22.
66.
Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74.PubMedCentralCrossRefPubMed
67.
Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19(S1):34–6.CrossRefPubMed
68.•
Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93–7. Landmark trial in Nature demonstrating the first pharmaceutical able to directly target amyloid deposits for enhanced clearance.PubMedCentralCrossRefPubMed
Metadata
Title
Emerging Advances in the Management of Cardiac Amyloidosis
Authors
Michael N. Vranian
Brett W. Sperry
Jason Valent
Mazen Hanna
Publication date
01-11-2015
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 11/2015
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-015-0653-1

Other articles of this Issue 11/2015

Current Cardiology Reports 11/2015 Go to the issue

Public Health Policy (TA Gaziano, Section Editor)

CVD Prevention Through Policy: a Review of Mass Media, Food/Menu Labeling, Taxation/Subsidies, Built Environment, School Procurement, Worksite Wellness, and Marketing Standards to Improve Diet

Hypertension (WB White and AJ Peixoto, Section Editors)

Is It Daily, Monthly, or Yearly Blood Pressure Variability that Enhances Cardiovascular Risk?

Heart Failure (MR Mehra and E Joyce, Section Editors)

Autonomic Modulation in Heart Failure: Ready for Prime Time?

Hypertension (WB White and AJ Peixoto, Section Editors)

What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease?

Peripheral Vascular Disease (MR Jaff, Section Editor)

Management of Aortic Aneurysms: Is Surgery of Historic Interest Only?

Stroke (D Wang, Section Editor)

The Year Embolectomy Won: a Review of Five Trials Assessing the Efficacy of Mechanical Intervention in Acute Stroke